Vaccination against Cervical Cancer: Profile of Accommodating Parents and Some Suggestions to Overcome Hesitancy against Vaccination
Tassang Andrew,G. E. Halle Ekane,C. Neh Fru,Frederick Nchang Cho,Tassang Thierry,T. Palle Ewane,P. Ngum Fru,Daniel Ndongo,W. Ndakason,G. Ncham,Tangui Gracious +10 more
- 01 Feb 2021
- pp 33-43
TL;DR: This poster presents a selection of images from the archives of the University of Buea, Cameroon, showing the history of infectious disease in the region and some of the institutions that dealt with it.
read more
Abstract: Faculty of Health Sciences, Department of Obstetrics and Gynecology, University of Buea, Cameroon. 2 Buea Regional Hospital Annex, Cameroon. Atlantic Medical Foundation Hospital – Mutengene, Cameroon. 4 Faculty of Social and Management Sciences, Department of Sociology and Anthropology, University of Buea, Cameroon. 5 Faculty of Sciences, Department of Biochemistry and Molecular Biology, University of Buea, Cameroon. Infectious Disease Laboratory, Faculty of Health Sciences, University of Buea, P.O.Box 63, Buea, Cameroon. Kumbo Sub Divisional Hospital, Kumbo, Cameroon. 8 Baptist Hospital Mutengene, Cameroon.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Determinants of Awareness and Knowledge on Cervical Cancer among Women in Buea- Cameroon
C. Neh Fru,Tassang Andrew,Frederick Nchang Cho,Tassang Thierry,P. Ngum Fru +4 more
- 26 Oct 2020
TL;DR: The number of sex partners for the last five years, age, educational level, and marital status were determinants affecting awareness and knowledge in this study.
Knowledge and Risk Factors of Cervical Cancer among Women in Towns of Fako Division- Cameroon
Tassang Andrew,Celestina Neh Fru,Mike Robert Brady,Frederick Nchang Cho,Tassang Thierry,Ngum Fru Paulette,Tangi Gracious,Toh Renald +7 more
TL;DR: None enhancement of lifestyle as the voluntary refusal of cervical cancer screening and CC vaccination has also been risky for CC.
References
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
Jan M. M. Walboomers,M. V. Jacobs,M. M. Manos,Franz X. Bosch,J. A. Kummer,Keerti V. Shah,Peter J.F. Snijders,Julian Peto,Chris J.L.M. Meijer,Nubia Muñoz +9 more
TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
9.3K
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.
TL;DR: A majority of ICC was associated with HPV16 or 18 in all regions, but approximately a quarter of all ICC cases were associated with one of 16 other HPV types, their distribution varying by region.
Worldwide burden of cervical cancer in 2008
Marc Arbyn,Marc Arbyn,Xavier Castellsagué,S de Sanjosé,Laia Bruni,Mona Saraiya,Freddie Bray,Jacques Ferlay +7 more
TL;DR: In spite of effective screening methods, cervical cancer continues to be a major public health problem and new methodologies of cervical cancer prevention should be made available and accessible for women of all countries through well-organised programmes.
1.2K
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.
TL;DR: A meta‐analysis of HPV type‐specific prevalence data published from 1990 to 2010 found that overall HPV prevalence increased significantly and the proportion of ICC associated with HPV16 and/or 18 (HPV16/18) was between 70 and 76% in all world regions except Asia.
1K
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years
Darron R. Brown,Susanne K. Kjaer,Kristjan Sigurdsson,Ole-Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo L. Pérez,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven-Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Elmar A. Joura,Robert J. Kurman,Slawomir Majewski,N. Munoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine Bryan,Lisa Lupinacci,Katherine E. D. Giacoletti,Heather L. Sings,Margaret James,Teresa M. Hesley,Eliav Barr +35 more
TL;DR: These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and -18 and are needed to fully ascertain the population-based impact and public health significance of these findings.
683